<DOC>
	<DOCNO>NCT01656902</DOCNO>
	<brief_summary>For cartilage cell product NOVOCART® 3D plus , use study describe , company TETEC AG obtain expand production authorization medication monitoring authority compliance Section 13 , Para . 1 Medicinal Products Act 2003 . This entitle TETEC AG produce pharmaceutical product already distribute . More 6000 patient already successfully treat NOVOCART® 3D Europe since 2003 . In order obtain general market authorization NOVOCART® 3D plus , control group study conduct , superiority safety effectiveness carrier-bound Autologous Chondrocyte Transplantation NOVOCART® 3D plus compare standard care microfracture surgery need proven . This study aim develop validate know new biologic marker quality clinical efficacy product request context identity , purity potency characteristic medicinal/investigational product . The patient receive one therapeutic procedure study . The treatment procedure use decide previously specify random process . This type study meet high quality requirement statutorily specify safety quality regulation also refer `` Good Clinical Practice '' ( GCP ) . The probability patient allocate one two treatment 2:1 ; , approx . 67 % probability therapy NOVOCART® 3D plus approx . 33 % probability therapy microfracture . Neither patient , investigator able influence treatment assignment . Patients screen eligibility Screening Visit . Each patient remain study 36 month post-implant effectiveness assessment , additional two year complete plan post-market phase . Each patient study five year . Cells tissue collect study use vitro-controlled experiment aim develop validate know novel biologic marker quantify cell quality context identity , purity potency . Prognostic value biologic marker examine correlate clinical data collect study .</brief_summary>
	<brief_title>Phase III Study Evaluate Safety Effectiveness NOVOCART 3D Plus vs. Microfracture Treat Cartilage Defects Knee</brief_title>
	<detailed_description />
	<mesh_term>Cartilage Diseases</mesh_term>
	<criteria>1 . Patient 18 65 year old screening . 2 . Patient localize articular cartilage defect femoral condyle trochlea knee . 2 localized cartilage defect accept total defect size ≤ 6 cm2 size individual lesion ≥ 2 cm2 , cartilage defect locate femoral condyle and/or trochlea cartilage defect treat NOVOCART 3D plus microfracture . 3 . Patient defect size 2 6 cm2 . Note : defect size estimate MRI visit 1 data available medical history . 4 . Patient intact articulate joint surface ( high Grade 2 International Cartilage Repair Society classification , kiss lesion ) . Note : ICRS classification estimate MRI visit 1 data available medical history . 5 . Patient intact meniscus ; maximum 50 % resection allow . Note : status meniscus estimate visit 1 data available medical history . 6 . Patient stable knee joint sufficiently reconstruct ligament . If , ligament repair must do , within 6 week cartilage treatment ( ACT/microfracture ) . 7 . Patient free range motion affect knee joint ≤ 10° extension flexion loss . 8 . Patient defectgrade III IV accord ICRS classification . Note : ICRS classification estimate MRI visit 1 data available medical history . 9 . Patient baseline score 60/100 2000 International Knee Documentation Committee ( IKDC ) subjective knee evaluation . 10 . Patient willing able give write informed consent participate study comply study requirement , include attend followup visit assessment postoperative rehabilitation regimen . 11 . Mandatory France : Patient benefit health insurance regimen . Exclusion Criteria ( preoperative ) : 1 . Patient investigator subinvestigator , research assistant , pharmacist , study coordinator , staff relative thereof directly involve conduct study . 2 . Patient unable undergo magnetic resonance imaging ( MRI ) . 3 . Patient prior surgical treatment target knee use mosaicplasty , autologous chondrocyte transplantation and/or microfracture . Note : prior diagnostic arthroscopy debridement lavage acceptable . Ligament repair accept , perform , within 6 week cartilage treatment ( ACT/microfracture ) . 4 . Patient radiologically apparent degenerative joint disease target knee determine Kellgren Lawrence grade &gt; 2 ( see Appendix A ) . 5 . Patient chronic inflammatory arthritis and/or infectious arthritis . 6 . Patient joint space narrow &gt; 1/3 target knee compare knee small 3 mm joint space measure xray . 7 . Patient malalignment ( valgus varusdeformity ) target knee . Note : In suspected case , mechanical axis must establish radiographically complete leg image stand position a.p . rather p.a . projection . The Mikulicz line allow deviate 5 mm eminentia intercondylaris . If alignment necessary , surgery perform , within 6 week cartilage treatment ( ACT/microfracture ) . 8 . Patient prior surgical treatment clinical relevance target knee . 9 . Patient osteochondral defect . 10 . Patient bilateral low limb pain low back pain . 11 . Patient known systemic connective tissue disease . 12 . Patient current uncontrolled diabetes . 13 . Patient known history autoimmune disease . 14 . Patient known history immunological suppressive disorder take immunosuppressant . 15 . Patient currently systemically intraarticularly take steroid and/or use steroid within last 30 day prior screen visit 1 . 16 . The patient history HIV/AIDS . 17 . The patient history syphilis ( Treponema pallidum ) . 18 . The patient active hepatitis B C infection verify antigen . Note : Patients cure hepatitis B C infection and/or verify antibody exclude . 19 . The patient site surgery active systemic local microbial infection , eczematization inflammable skin alteration ( include protozoonosis : Babesiosis , Trypanosomiasis ( e.g . ChagasDisease ) , Leishmaniasis , persistent bacterial infection , like Brucellosis , spot typhus fever , Rickettsiosis , Leprosy , Recurrent Fever , Melioidosis Tularaemia ) . 20 . Patient known history cancer within past 5 year . 21 . Patient known history osteoporosis ; also patient primary hyperparathyroidism hyperthyroidism without satisfactory treatment , chronic renal failure patient prior pathological fracture independent genesis exclude . 22 . Patient degenerative muscular neurological condition would interfere evaluation outcome measure include limit Parkinson 's disease , amyotrophic lateral sclerosis ( ALS ) , multiple sclerosis ( MS ) . 23 . Patient body mass index ( BMI ) high 35 kg/m2 . 24 . Patient woman pregnant lactating . Note : contraception indicate female patient childbearing potential day cartilage treatment . Female patient unwilling practice medically acceptable method birth control day cartilage treatment include . 25 . Patient currently participate , participate clinical study within 3 month prior screen visit . 26 . Patient know current recent history illicit drug alcohol abuse dependence 27 . Patient psychiatric cognitive impairment , opinion investigator , would interfere patient 's ability comply study requirement , e.g. , Alzheimer 's disease . 28 . Patient condition , , opinion investigator , would make patient unsuitable study . 29 . Mandatory France : patient test positive Human TCell Lymphotropic Virus Types 1 2 ( HTLV1 2 ) Intraoperative 1 . Patient pregnant confirm urine pregnancy test arthroscopy . 2 . Patient localize articular cartilage defect femoral condyle trochlea knee . 2 localized cartilage defect accept total defect size 6 cm2 size individual lesion least 2 cm2 , cartilage defect locate femoral condyle and/or trochlea cartilage defect treat NOVOCART 3D plus microfracture . 3 . Patient defect size 2 6 cm2 postdebridement . 4 . Patient intact articulate joint surface ( least ( high ) Grade 2 International Cartilage Repair Society classification ) kiss lesion ) . 5 . Patient intact meniscus ; maximum 50 % resection allow ( indication concurrent meniscus transplant ) . 6 . Patient stable knee joint sufficiently reconstruct ligament . If , ligament repair must do within 6 week cartilage treatment ( ACT/microfracture ) . 7 . Patient defect grade III IV accord ICRS classification .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>October 2016</verification_date>
	<keyword>Autologous Chondrocyte Transplantation</keyword>
	<keyword>NOVOCART 3D plus</keyword>
	<keyword>knee joint pain</keyword>
	<keyword>safety</keyword>
	<keyword>efficacy</keyword>
	<keyword>treatment</keyword>
	<keyword>TETEC</keyword>
	<keyword>cartilage</keyword>
	<keyword>ACT</keyword>
	<keyword>cartilage repair</keyword>
	<keyword>tissue</keyword>
	<keyword>MOCART</keyword>
</DOC>